Skip to content
WELCOME10 — 10% OFF YOUR FIRST ORDER  ·  FREE SHIPPING OVER $300 CAD  ·  COA ON EVERY ORDER
Research Comparison

IGF-1 vs Tirzepatide

IGF-1 and Tirzepatide are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.

Shared research areas:Metabolic
Class70-residue single-chain protein (native IGF-1), three disulfide bondsLipidated dual receptor agonist (GIP / GLP-1), 39-residue chain
Molecular weight7648.7 g/mol4813.5 g/mol
CAS numberNot assigned / not specifiedNot assigned / not specified
Purity spec≥99%≥99%
Research areasHormonal & Endocrine, Musculoskeletal, MetabolicMetabolic
Primary diluentDilute acetic acid for initial dissolutionBacteriostatic water (0.9% benzyl alcohol)
Working windowShort — days rather than weeks — and shorter still with repeated handling.Commonly worked with for 4–6 weeks at 2–8 °C.
Lead degradation routeMisfolding and irreversible denaturation — the dominant failure mode.Interfacial aggregation from agitation or freezing — the dominant practical route.
Freeze–thawPoorly tolerant. Repeated freeze-thaw denatures the folded structure permanently, so aliquot for single use rather than relying on any freeze tolerance.Do not freeze reconstituted solution. Interfacial aggregation during freezing is the characteristic failure mode and is irreversible.
Light sensitivityNo specific light requirement beyond normal practice.No specific light requirement beyond normal practice.

How they actually differ

Comparing the two: IGF-1 is 70-residue single-chain protein (native igf-1), three disulfide bonds, while Tirzepatide is lipidated dual receptor agonist (gip / glp-1), 39-residue chain — different molecular classes with different handling consequences; they call for different primary diluents (dilute acetic acid for initial dissolution versus bacteriostatic water (0.9% benzyl alcohol)); their leading degradation routes differ (misfolding and irreversible denaturation for IGF-1, interfacial aggregation from agitation or freezing for Tirzepatide), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.

IGF-1 — origin

IGF-1 is the native insulin-like growth factor — a folded 70-amino-acid protein stabilised by three internal disulfide bonds. It is the downstream messenger produced after growth hormone acts, and it is handled as a protein rather than a short peptide. This is the native sequence, distinct from the long-acting LR3 analogue.

Tirzepatide — origin

Tirzepatide is built on a GIP-based backbone rather than a GLP-1 one — an important and often-missed design detail. It was engineered from the GIP sequence and modified to acquire GLP-1 receptor activity, with a C20 fatty diacid attached via a linker for albumin binding. The term "twincretin" describes the dual incretin activity.

IGF-1 research themes

IGF-1 receptor signalling

Studied as the native ligand for the IGF-1 receptor and its downstream proliferation and survival pathways.

Satellite cell activation

Examined in muscle research models for its role in satellite-cell behaviour and anabolic signalling.

Native versus analogue

Compared with IGF-1 LR3, whose reduced binding-protein affinity gives a longer active window — a contrast studied directly in the literature.

Tirzepatide research themes

Dual incretin engagement

Simultaneous GIP and GLP-1 receptor activity from a GIP-derived backbone.

Insulin secretion and glucagon suppression

Core metabolic research endpoints for the incretin class.

Gastric emptying

A well-characterised GLP-1 pathway effect studied in metabolic models.

GIP receptor pharmacology

Whether GIP agonism or antagonism is the productive direction remains an active research debate.

IGF-1 handling

  • Dissolve first in dilute acetic acid, then dilute into the working buffer — never expect plain water to take it up fully.
  • Use a carrier protein and low-bind labware to prevent adsorptive loss.
  • Aliquot for single use; do not re-freeze reconstituted protein.

Tirzepatide handling

  • Swirl, never shake or vortex.
  • Add diluent down the vial wall and give the cake time — several minutes of slow dissolution is normal, not a defect.
  • Store upright and refrigerated; do not freeze once reconstituted.

Both third-party tested

Every Popular Peptides batch of IGF-1 and Tirzepatide is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.

Verify a batchPublished COAsHow we test

IGF-1 reference

Full IGF-1 reference IGF-1 storage IGF-1 reconstitution IGF-1 calculatorIGF-1 product details

Tirzepatide reference

Full Tirzepatide reference Tirzepatide storage Tirzepatide reconstitution Tirzepatide calculatorTirzepatide product details

Related comparisons

5-Amino-1MQ vs IGF-15-Amino-1MQ vs TirzepatideCJC-1295 (No DAC) vs IGF-1CJC-1295 (No DAC) vs TirzepatideCJC-1295 + Ipamorelin vs IGF-1CJC-1295 + Ipamorelin vs TirzepatideIGF-1 LR3 vs TirzepatideIGF-1 vs IGF-1 LR3

IGF-1 and Tirzepatide are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.